‘Remarkable' pancreatic cancer jab offers longer survival hope for patients
The jab has given hope to patients after a trial found it increased the survival of participants with pancreatic cancer.
Researchers described the findings as 'remarkable' and have already started testing the efficiency of the jab among a larger group of pancreatic and bowel cancer patients.
The jab uses a new type of immunotherapy, designed to improve vaccine delivery to the lymph nodes, which help the body fight infections and disease.
Pancreatic and bowel cancers frequently carry a mutation in a gene called KRAS, which plays a key role in tumour growth, and scientists developed the jab to recognise and attack this gene.
The study, published in the journal Nature Medicine, tested the jab on 20 patients with pancreatic cancer and five with bowel cancer.
When participants were followed up after 20 months, 68 per cent had developed strong immune responses specific to mutant KRAS tumour proteins.
Participants who had the strongest immune responses lived and stayed cancer-free for longer than those with weaker responses.
Some patients survived about two years and five months after receiving the vaccine.
In comparison, just three in 10 people diagnosed with pancreatic cancer survive for a year.
Pancreatic cancer has some of the poorest survival rates due to late detection. It doesn't usually cause symptoms in the early stages, and as it grows, it can cause tummy pain, yellowing of the skin, unexplained weight loss and changes in stools.
Many patients see their cancer returning even after treatments such as radiotherapy and chemotherapy.
But the trial showed the jab could help prevent the cancer from returning for more than 15 months.
Unlike other cancer jabs which are personalised to individual patients, this vaccine, ELI-002 2P, has a single version which can be given to all patients meaning it can be manufactured in bulk and given more rapidly.
Dr Dani Edmunds, research information manager at Cancer Research UK, said: 'It's promising to see that vaccines could help people with pancreatic and bowel cancer live cancer-free for longer.'
'More research is needed to understand why some people benefit from the vaccine while others don't, so that we can make sure we're beating cancer for everyone,' he added.
Professor Richard Sullivan, director of the Centre for Conflict and Health Research at King's College London, has suggested more research is needed.
'There is some interesting science in this study, but this is a long way from proving any sort of clinical utility,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
I lost both parents to cancer. It taught me you have to lean into your grief.
Before my mom was diagnosed with esophageal cancer at 69, she was the epitome of good health. Her death less than five months later, in July 2024, was — and still is — a total shock. Grief comes in waves — long-lasting with a killer crash. Great for surfers, but not for us grievers. "So, Christine, I've got cancer," my mother calmly told me over the phone one February morning. I have no idea what I said next. All I can remember is what felt like lava slowly, painfully rising from the pit of my stomach up to my chest, where it just sat bubbling, searching desperately for somewhere to escape my body. A sensation I hadn't experienced for over 15 years, when I received a similar phone call from my father. What followed was the start of my double life, in which I split my time between my home in San Diego and Dublin, 5,199 miles away and the place my mom called home. Her treatment was supposed to be chemotherapy and maybe radiation before making a full recovery, but she never even got to that stage. She became an inpatient not long after that February phone call, and the following summer, on July 14, 2024, she died. My mother's death was — and still is — a total shock The thing about cancer is that you know death might be coming long before it arrives, or in my mom's case, not long at all. I tell myself this "advanced notice" is a good thing, a coping mechanism if you will. Before she got sick at 69, my mother was the epitome of good health — playing tennis and hiking the Irish Wicklow mountains weekly. The thought that something could harm her wasn't even on my radar. I had already lost one parent to cancer. The made-up rules of life that lived in my head said it simply was not possible to lose the other, and to the same disease, no less. The call that changed everything I was heading out the door when "mom" popped up on my phone. After weeks of a raspy voice and a doctor's appointment warning that "something sinister" was at play, my mom finally had a specialist consultation scheduled. I knew the call was coming, and unlike the far too many other times that I screened her call — how I wish now I had answered the phone to her more — this was one call I answered before it even got through the first ring. As soon as I picked up, I knew something was very wrong. Maybe it was her calm voice, procrastinating sharing the specialist's update by asking me how the weather was that day. Like me, my mom would often worry about the silliest of things that she'd dissect from every angle possible. Yet here she was calling me after an important appointment, sounding as calm as I'd ever heard her. Could everything be OK? No, because if it were, I'm sure the first thing she would've said was how bad she felt for wasting everyone's time. I gave my mom a few minutes of grace when it came to the chit-chat. I too, wanted to pretend for a few minutes longer that everything was fine, normal, and no one was dying anytime soon. That's when she told me the news: it was esophageal cancer. My double life between California and Dublin I'd spend three weeks in Ireland before escaping to California for a week, where I could avoid the pain of seeing my mom go through the symptoms that come with that horrible disease. Life would start to feel normal again, but reality would always sneak in. I'd see a message pop up on our family WhatsApp group — "Hey mom, heading into the hospital now" from my sister, or "Can you bring in tissues?" from my mom. Painful reminders that I wasn't there. Once my San Diego "break" was up, it was back to my Dublin life where I had quickly developed a new routine. Every morning, I would drive to the hospital and pick up two iced lattes (or hot, depending on the Irish weather that day) for my mom and me to enjoy together. My mom couldn't actually drink the coffee I bought her. She had a tracheostomy and no ability to swallow, so she would just sip the latte, slush it around her mouth, and spit it out. But she absolutely loved it. Don't tell my siblings, but I'm 99% sure it was the highlight of her day. We were simply doing what normal moms and daughters do — catching up over a coffee. I probably had more coffee catch-ups with her in those four-ish months than I had in years. Realizing that leaves a pit in my stomach. My mom passed away less than five months after that February phone call After the funeral, I returned to San Diego feeling relieved that I could settle back into a normal life. I could unpack my suitcase, and for the first time in months, put it away. That initial relief lasted for a few weeks, but my birthday hit a month later, and not waking up to a sweet birthday card or text from my mom was one of the first moments of reality setting in. My husband tells me that grief comes in waves — sometimes it's a small ripple that comes and goes, oftentimes when I'm not expecting it. Just the other day, I opened a Clarins moisturizer and boom, the grief hit. My mom used Clarins for as long as I can remember, and the smell of it took me right back to the master bathroom of her house in Dublin, where I'd bug her to borrow it while I was visiting because I would always forget to bring my own. I paused to take her in for that short moment, and then it was over. Sometimes the waves are the type a surfer dreams of — long-lasting with a killer crash. Great for surfers, not so much for us grievers. You have no idea how long the grief is going to last, and you can't get out of it. You just have to wait for the crash to come. I've listened to Calm's grief podcast series, I've read books like Edith Eger's "The Gift" exploring how to overcome grief, but there's no healing it. The sad reality is that there isn't a pretty bow you can wrap around death. You can't "hope" because the worst has already happened, but you can appreciate what you had. And if you're one of the lucky ones, you just have to pick up the phone next time you see "mom" pop up. Read the original article on Business Insider Solve the daily Crossword
Yahoo
12 minutes ago
- Yahoo
BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) ('BriaCell' or the 'Company'), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce its acceptance into Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the clinical development of Bria-OTS+, BriaCell's next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. As one of the world's foremost cancer research and treatment institutions, MSK has more than 135 years of leadership in patient care, education and discovery. Through the MSK Therapeutics Accelerator Cohort program, BriaCell will explore access to MSK's expertise and institutional resources, including GMP manufacturing services, Investigational New Drug (IND) Application preparation and submission and regulatory strategy support to expedite Bria-OTS+ development. 'We are honored to work with the scientific and clinical experts at MSK Therapeutics Accelerator,' stated Dr. William V. Williams, BriaCell's President and CEO. 'MSK's deep expertise in cancer therapy development and state-of-the-art resources make it an ideal partner to accelerate our personalized off-the-shelf immunotherapy platform.' 'We are excited to welcome BriaCell into the cohort program,' stated Eileen Flowers, PhD, Director, Technology Development & Licensing, in the Office of Entrepreneurship and Commercialization at MSK. 'We believe Bria-OTS+ has the potential to transform cancer care, offering meaningful advances in efficacy and safety for thousands of patients,' stated Dr. Miguel Lopez-Lago, BriaCell's Chief Scientific Officer. 'Our participation in this cohort program is yet another step towards achieving that vision.' About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at Safe Harbor This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release, including statements regarding the Company's beliefs that the collaboration with the Memorial Sloan Kettering Cancer Center could propel the clinical development of Bria-OTS+; the specific topics that the MSK Therapeutics Accelerator Cohort will explore and discuss; the Company exploring access to MSK's expertise and institutional resources; and the Company's beliefs regarding Bria-OTS+'s potential to transform cancer care and offer meaningful advances in efficacy and safety for thousands of patients, are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 'Risks and Uncertainties' in the Company's most recent Management's Discussion and Analysis, under the heading 'Risk Factors' in the Company's most recent Annual Information Form and under 'Risks and Uncertainties' in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at and on EDGAR at Forward-looking statements contained in this announcement are made as of this date and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@ Investor Relations Contact:investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
14 minutes ago
- Medscape
Little-Known Gut Nutrient Is Emerging Player in Cancer Fight
An under-the-radar micronutrient is having a moment. Queuosine — just call it 'Q' — is a molecule that humans can only get from foods and gut bacteria. It's has been known to microbiologists for decades, who know it plays a role in protein synthesis — as well as cancer growth, brain health, and inflammation. Yet, it hasn't been clear how Q moves from the gut into cells throughout the body. Now the curtain has been pulled back. The authors of a study published in Proceedings of the National Academy of Sciences ( PNAS ) have pinpointed a gene ( SLC35F2 ) that helps transport Q to cells. The researchers say the new finding could help scientists figure out how to use the micronutrient to fight disease. 'It's 70 years ago now that Q was discovered,' said study author Vincent P. Kelly, PhD, Professor of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. 'What's exciting about this study is the fact that we never understood how we actually took that molecule from bacteria in our body and transported it into our cells, and this explains how we do it.' Q: A Brief Primer The PNAS study looked at both queuine (q), a modified nucleobase, and its nucleoside Q. A quick refresher: A nucleobase is a nitrogen-containing molecule that is one of the building blocks of DNA and RNA. And a nucleoside is a molecule made of sugar (either ribose or deoxyribose) plus a nitrogenous base (purine or pyrimidine) — also a building block of DNA. All of the cells in the human body are eukaryotes — they have a nucleus — and they rely on the micronutrients Q and q, which lurk in the human gut. They come from gut bacteria or a person's diet (most commonly meat, eggs, dairy, fruits and vegetables, and fermented foods), said Kelly. Prior studies had given hints that cellular uptake of Q and q is mediated by a selective transporter, but Kelly said that this transporter's identity 'remained elusive' until now. 'Almost all eukaryotes take the Q molecule and incorporate it into the transfer RNA (tRNA) in the body,' said Kelly. 'tRNA is critical for making protein. It's essential — essential for everything,' he said, pointing out that the average adult human is composed of about 12 kilograms (26 pounds) of protein. How does Q get into gut bacteria and the food we eat? The Q molecule is more or less everywhere, Kelly said. 'It's in the oceans, it's in the soil. Plants, which are eukaryotic, take it from the soil. And yet, very little is known about it. I'm surprised more people aren't knowledgeable about it,' he said, especially considering public interest over the years in health-oriented micronutrients like vitamins and 'macros' like carbohydrates, fats, and proteins. What They Found, What It Means Collaborating with researchers from Germany, Northern Ireland, the United States, and his own colleagues in Ireland, Kelly said they used a cross-species bioinformatic search and genetic validation — research techniques that enable scientists to analyze vast amounts of genomic data from across different species — to determine that Q and q are 'salvaged' from the gut by SLC35F2 and ferried to different tissues throughout the body. 'There's a whole biology built around this micronutrient,' said Kelly. Cracking the identity of the transporter of Q and q opens up opportunities for important research, Kelly said. It will lead to a deeper understanding of how intracellular levels of both micronutrients are regulated and how their deficiency is associated with diseases. The study findings 'represent an important leap in our understanding of queuosine biology. Queuosine is a unique tRNA modification to its precursor, queuine, which is not synthesized de novo in mammalian cells,' said Sherif Rashad, MD, PhD, Associate Professor in the Graduate School of Biomedical Engineering and the Graduate School of Medicine at Tohoku University in Sendai, Japan. Rashad said scientists' understanding of how q is imported into cells was 'virtually nonexistent' until now and that the authors of the PNAS study used 'an elegant but grounded approach' to identify the first q importer. The finding 'paves the way for new discoveries in the many fields at the crossroads of queuosine biology,' he said. Zdeněk Paris, PhD, Head of Laboratory, in the Laboratory of RNA Biology of Protists, at the Institute of Parasitology in Ceske Budejovice, Czech Republic, agreed. 'This study advances the field of queuosine research by identifying the primary transporter and establishing a direct link between the function of SLC35F2, intracellular queuosine levels, and vital cellular processes, which can explain how a deficiency of Q and/or its free base, queuine (q), contributes to various conditions, including neurological disorders and cancer.' Paris said, 'Prior to this study, no specific transporters for the intracellular uptake of Q or q had been identified in any eukaryote.' He said the research is 'high-quality.' He pointed out that the researchers also demonstrated that SLC35F2 is the sole high-affinity plasma membrane transporter for the Q nucleoside and the primary high-affinity transporter for the nucleobase q in human cells. 'Its high expression in the human alimentary canal strongly suggests a critical role in Q/q uptake from the gut during digestion,' he said. 'This reveals how these micronutrients, which are synthesized exclusively by bacteria, are salvaged from the gut microbiome and/or diet and delivered to various body tissues. Based on the obtained data, the authors propose a model in which Q is transported from the gut to the liver by SLC35F2 . There, QNG1 cleaves Q to release the q base, which enters the serum for wider distribution.' The Cancer Connection Paris said that SLC35F2 was characterized as an oncogene in previous research and is known to contribute to the progression of various cancers through its overexpression, including non-small cell lung cancer, papillary thyroid cancer, and bladder cancer. Paris added that SLC35F2 's role in Q and q transport provides a significant mechanistic explanation for its oncogenic activity. 'High SLC35F2 expression is an unfavorable prognostic factor for patient survival in multiple cancers. SLC35F2 overexpression increases cellular Q/q levels, promoting higher Q34 modification of tRNAs. Consequently, Q modification may offer malignant cells a selective advantage through codon-biased translation,' he said. Additionally, the study identified SLC35F2 (or its homologs) as the unique Q/q transporter in the yeast Schizosaccharomyces pombe and the human parasite Trypanosoma brucei , Paris said. 'While the physiological importance of Q-tRNA varies by species — for example, loss of Qtp1 does not affect growth in S pombe or T brucei — this comparative analysis strengthens the evidence for SLC35F2 's role in humans and reveals its conserved function in eukaryotes that salvage Q and q.' He said, 'In essence, the study provides the missing link in the queuine salvage pathway, significantly advancing our understanding of how this essential micronutrient is acquired, distributed, and regulated, and its profound impact on health and disease, particularly in the context of cancer.'
